Chief Medical Officer of $ATHA sells 1,644 shares in insider sale

The CHIEF MEDICAL OFFICER of the company $ATHA, Martin Javier San, recently engaged in insider trading by selling 1,644 shares on 01-02-2026, amounting to approximately $11,310. This transaction represented around 13.9% of their holdings in this class of stock, leaving them with 10,189 shares of $ATHA. Over the past 6 months, $ATHA insiders have carried out 5 transactions on the open market, with all instances involving sales rather than purchases.

Among the recent insider trades within the company, Mark James Litton, President, and CEO sold 2,586 shares for an estimated $17,791. The CHIEF MEDICAL OFFICER, Martin Javier San, sold 1,644 shares for $11,310. In addition, Kevin Church, the CHIEF SCIENTIFIC OFFICER, sold 876 shares for an estimated $6,026, while Mark Worthington, General Counsel, and CCO, and Robert Renninger, Chief Financial Officer, each sold 876 and 297 shares, respectively, for around $6,026 and $2,043.

A separate aspect of $ATHA’s financial activities includes hedge fund maneuvers. Notably, 5 institutional investors have added to their $ATHA holdings, while 41 have reduced their positions in the most recent quarter. The notable transactions involve entities such as PROPEL BIO MANAGEMENT, LLC, SIMPLIFY ASSET MANAGEMENT INC., TANG CAPITAL MANAGEMENT LLC, BANK OF AMERICA CORP /DE/, ACADIAN ASSET MANAGEMENT LLC, BLACKROCK, INC., and PATHSTONE HOLDINGS, LLC, all reducing their share amounts significantly in the third quarter of 2025.

For more insights into insider and hedge fund transactions involving $ATHA stock, individuals can access Quiver Quantitative’s dashboards tracking these movements. It is essential to note that the information provided in this article is solely for informational purposes and does not constitute financial advice. Individuals should refer to Quiver Quantitative’s disclaimers for a comprehensive understanding of these transactions.